The immune checkpoint inhibitor, nivolumab, either alone or in combination with the CTLA-4 inhibitor ipilimumab, has also been previously approved in patients with MSI metastatic colorectal cancer who have been previously treated with systemic therapies [22,23]. The gene discussed is CTLA4; the disease is metastatic colorectal cancer.